Eli Lilly will buy Ventyx Biosciences in an all-cash deal worth $1.2 billion, the companies said on Wednesday, marking the ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

A deal for Ventyx would help Lilly compete in the promising space. If Ventyx’s experimental pills pan out, they would add to ...

In this week’s edition of InnovationRx, we look at a former Wall Street analyst’s $4 billion obesity drug company, Wegovy’s ...

Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

Jan 6 (Reuters) - Eli ‌Lilly ​is in advanced ‌talks to buy Ventyx ​Biosciences for more than $1 billion, ‍the Wall Street ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Indiana Attorney General Todd Rokita on Monday announced a new lawsuit against Indianapolis-based drug maker Eli Lilly and Co ...

Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients ...

Shortly after securing a partnership with Sanofi, InduPro is linking up with Eli Lilly in efforts to discover new cancer ...

Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences.